(firstQuint)Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1.

 Phase 3, open-label, single-arm, single-dose, study of AVXS-101 (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by nonfunctional survival motor neuron 1 gene (SMN1) with 1 or 2 copies of survival motor neuron 2 gene (SMN2).

 Fifteen (15) patients < 6 months (< 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.

.

 Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1@highlight

Phase 3 pivotal US trial studying open-label intravenous administration of AVXS-101 in SMA Type 1 patients